AstraZeneca settles FCPA case with SEC for $5.5M

Biopharmaceutical-company AstraZeneca has reached a $5.5 million settlement with the SEC to settle claims that it violated the Foreign Corrupt Practices Act by making improper payments to state-controlled healthcare providers in China and Russia. Jaclyn Jaeger reports.

WELCOME TO OUR OPEN HOUSE – LOG IN TO CONTINUE READING FOR FREE

If you are already a registered user or a member, SIGN IN now.